142 related articles for article (PubMed ID: 32411379)
1. Haplotype-specific PCR for
Wichukchinda N; Pakdee J; Kunhapan P; Imunchot W; Toyo-Oka L; Tokunaga K; Mahasirimongkol S
Hum Genome Var; 2020; 7():13. PubMed ID: 32411379
[TBL] [Abstract][Full Text] [Related]
2.
Mthiyane T; Millard J; Adamson J; Balakrishna Y; Connolly C; Owen A; Rustomjee R; Dheda K; McIlleron H; Pym AS
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964788
[TBL] [Abstract][Full Text] [Related]
3. N-acetyltransferase 2 enzyme genotype-phenotype discordances in both HIV-negative and HIV-positive Nigerians.
Kotila OA; Fawole OI; Olopade OI; Ayede AI; Falusi AG; Babalola CP
Pharmacogenet Genomics; 2019 Jul; 29(5):106-113. PubMed ID: 30882558
[TBL] [Abstract][Full Text] [Related]
4. [The associations of polymorphism of N-acetyltransferase 2 gene is associated with antituberculosis drug-induced hepatotoxicity in tuberculosis patients].
An HR; Wu XQ; Wang ZY; Liang Y; Zhang JX
Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Jan; 45(1):36-40. PubMed ID: 21418817
[TBL] [Abstract][Full Text] [Related]
5. Arylamine N-acetyltransferase 2 gene polymorphism in an Algerian population.
Chelouti H; Khelil M
Ann Hum Biol; 2017 Sep; 44(6):531-536. PubMed ID: 28347189
[TBL] [Abstract][Full Text] [Related]
6. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests.
Bozok Cetintaş V; Erer OF; Kosova B; Ozdemir I; Topçuoğlu N; Aktoğu S; Eroğlu Z
Tuberk Toraks; 2008; 56(1):81-6. PubMed ID: 18330759
[TBL] [Abstract][Full Text] [Related]
7. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
[TBL] [Abstract][Full Text] [Related]
9. N-acetyltransferase 2 polymorphism and acetylation profiles in Buginese ethnics of Indonesia.
Yuliwulandari R; Susilowati RW; Razari I; Viyati K; Umniyati H; Prayuni K
Ann Hum Genet; 2019 Nov; 83(6):465-471. PubMed ID: 31332782
[TBL] [Abstract][Full Text] [Related]
10. Genetic heterogeneity among slow acetylator N-acetyltransferase 2 phenotypes in cryopreserved human hepatocytes.
Doll MA; Hein DW
Arch Toxicol; 2017 Jul; 91(7):2655-2661. PubMed ID: 28516247
[TBL] [Abstract][Full Text] [Related]
11. Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators.
Al-Ahmad MM; Amir N; Dhanasekaran S; John A; Abdulrazzaq YM; Ali BR; Bastaki S
Ann Hum Genet; 2017 Sep; 81(5):190-196. PubMed ID: 28653770
[TBL] [Abstract][Full Text] [Related]
12. Validation of PHASE for deriving N-acetyltransferase 2 haplotypes in the Western Cape mixed ancestry population.
Swart C; Meldau S; Centner CM; Marais AD; Omar F
Afr J Lab Med; 2020; 9(1):988. PubMed ID: 33392048
[TBL] [Abstract][Full Text] [Related]
13. Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients.
Singh N; Dubey S; Chinnaraj S; Golani A; Maitra A
Mol Diagn Ther; 2009; 13(1):49-58. PubMed ID: 19351215
[TBL] [Abstract][Full Text] [Related]
14. Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population.
Salazar-González R; Gómez R; Romano-Moreno S; Medellín-Garibay S; Núñez-Ruíz A; Magaña-Aquino M; Milán-Segovia RC; Portales-Pérez DP
Mol Biol Rep; 2014 Dec; 41(12):7833-43. PubMed ID: 25163630
[TBL] [Abstract][Full Text] [Related]
15. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients.
An HR; Wu XQ; Wang ZY; Zhang JX; Liang Y
Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):535-43. PubMed ID: 22506592
[TBL] [Abstract][Full Text] [Related]
16. Association of Cytochrome P450 2E1 and N-Acetyltransferase 2 Genotypes with Serum Isoniazid Level and Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Cross-Sectional Study.
Pourmohamadi N; Pour Abdollah Toutkaboni M; Hayati Roodbari N; Tabarsi P; Baniasadi S
Iran J Med Sci; 2023 Sep; 48(5):474-483. PubMed ID: 37786472
[TBL] [Abstract][Full Text] [Related]
17. NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.
Suvichapanich S; Fukunaga K; Zahroh H; Mushiroda T; Mahasirimongkol S; Toyo-Oka L; Chaikledkaew U; Jittikoon J; Yuliwulandari R; Yanai H; Wattanapokayakit S; Tokunaga K
Pharmacogenet Genomics; 2018 Jul; 28(7):167-176. PubMed ID: 29781872
[TBL] [Abstract][Full Text] [Related]
18. Re-investigation of the concordance of human NAT2 phenotypes and genotypes.
Bolt HM; Selinski S; Dannappel D; Blaszkewicz M; Golka K
Arch Toxicol; 2005 Apr; 79(4):196-200. PubMed ID: 15558239
[TBL] [Abstract][Full Text] [Related]
19. NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.
Yuliwulandari R; Prayuni K; Susilowati RW; M Sofro AS; Tokunaga K; Shin JG
Pharmacogenomics; 2019 Dec; 20(18):1303-1311. PubMed ID: 31699005
[No Abstract] [Full Text] [Related]
20. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD
Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
